|
Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. |
|
|
Travel, Accommodations, Expenses - Roche |
|
|
|
Consulting or Advisory Role - Celgene; Shire |
Speakers' Bureau - Celgene |
Travel, Accommodations, Expenses - Ipsen; Merck Serono |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Bayer; Ipsen; Merck Serono; Novartis/Pfizer; Sanofi |
Travel, Accommodations, Expenses - Amgen; Bayer; Ipsen; Novartis/Pfizer; Roche; Sandoz; Sanofi |
|
|
Honoraria - Celgene; Shire |
Consulting or Advisory Role - Celgene; Ethicon; Ipsen; Shire |
|
Research Funding - Celgene (Inst) |
Other Relationship - Cancer Care Ontario |
|
|
Consulting or Advisory Role - Bayer Schering Pharma; Bristol-Myers Squibb; BTG; GenoScience Pharma |
Travel, Accommodations, Expenses - Bayer; Ipsen; Merck |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Merck; Roche |
Travel, Accommodations, Expenses - Merck; Roche; SERVIER |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Merck; Novartis; Sanofi |
Travel, Accommodations, Expenses - Ipsen |
|
|
Honoraria - Bayer; Novartis; Sirtex Medical |
Consulting or Advisory Role - Ipsen; Sanofi |
Travel, Accommodations, Expenses - Bayer; Ipsen |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Bayer; Roche; SERVIER |
|
|
Honoraria - Amgen; Celgene; Lilly; Merck Serono; Novartis; Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; B. Braun |
Travel, Accommodations, Expenses - Eumedica; Ipsen |
|
|
No Relationships to Disclose |
|
|
|
Honoraria - Amgen; Bayer; Celgene; Merck Serono; Roche; Sanofi; SERVIER; Shire |
Consulting or Advisory Role - Amgen; Bayer; Merck Serono; SERVIER |
Travel, Accommodations, Expenses - Amgen; Merck Serono; Roche |